PMID- 34755024
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2514-1775 (Electronic)
IS  - 2514-1775 (Linking)
VI  - 5
IP  - Suppl 2
DP  - 2021 Nov
TI  - Rituximab for interstitial pneumonia with autoimmune features at two medical 
      centres.
PG  - ii1-ii9
LID - 10.1093/rap/rkab051 [doi]
AB  - OBJECTIVES: Many patients with interstitial lung disease (ILD) have autoimmune 
      manifestations but do not meet criteria for a systemic rheumatic disease. A 
      subset meets criteria for interstitial pneumonia with autoimmune features (IPAF) 
      and have ILD requiring therapy. We conducted a multicentre observational study to 
      examine the use of rituximab (RTX) in IPAF. METHODS: Patients from Mass General 
      Brigham (MGB) and University of Chicago Medicine (UCM) were included if they were 
      >/=18 years old, met the 2015 classification criteria for IPAF and were treated 
      with RTX. Clinical improvement was defined as improvement in four out of four 
      domains at 1 year after RTX initiation: documented clinician global assessment; 
      oxygen requirement; need for respiratory-related hospitalization; and survival. 
      RESULTS: At MGB, 36 IPAF patients (mean age 61 years, 44% female) were treated 
      with RTX. At 1 year, 18 (50%) were clinically improved, 12 (33%) were stable, and 
      6 (17%) died from progressive respiratory failure. At UCM, 14 IPAF patients (mean 
      age 53 years, 71% female) were treated with RTX. At 1 year, eight (57%) were 
      improved, two (14%) were stable, three (21%) died from progressive respiratory 
      failure, and one (7%) was lost to follow-up. Two patients experienced minor 
      infusion reactions, and two patients discontinued therapy owing to adverse events 
      (infections). CONCLUSION: In patients with IPAF treated with RTX at two medical 
      centres, the majority (40 [80%]) demonstrated improvement/stability at 1 year. 
      These findings call for prospective studies, including randomized clinical 
      trials, to determine the risks, benefits and cost effectiveness of RTX in IPAF.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology.
FAU - D'Silva, Kristin M
AU  - D'Silva KM
AUID- ORCID: 0000-0001-8370-4166
AD  - Division of Rheumatology, Allergy, and Immunology.
AD  - Clinical Epidemiology Program, Mongan Institute, Department of Medicine, 
      Massachusetts General Hospital, Harvard Medical School, Boston, MA.
FAU - Ventura, Iazsmin Bauer
AU  - Ventura IB
AD  - Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, 
      IL.
FAU - Bolster, Marcy B
AU  - Bolster MB
AD  - Division of Rheumatology, Allergy, and Immunology.
FAU - Castelino, Flavia V
AU  - Castelino FV
AD  - Division of Rheumatology, Allergy, and Immunology.
FAU - Sharma, Amita
AU  - Sharma A
AD  - Department of Radiology, Division of Thoracic Radiology, Massachusetts General 
      Hospital, Harvard Medical School, Boston, MA.
FAU - Little, Brent P
AU  - Little BP
AD  - Department of Radiology, Division of Thoracic Radiology, Massachusetts General 
      Hospital, Harvard Medical School, Boston, MA.
FAU - Adegunsoye, Ayodeji
AU  - Adegunsoye A
AD  - Section of Pulmonary and Critical Care, Department of Medicine, University of 
      Chicago, Chicago, IL.
FAU - Strek, Mary E
AU  - Strek ME
AD  - Section of Pulmonary and Critical Care, Department of Medicine, University of 
      Chicago, Chicago, IL.
FAU - Choi, Hyon
AU  - Choi H
AD  - Division of Rheumatology, Allergy, and Immunology.
AD  - Clinical Epidemiology Program, Mongan Institute, Department of Medicine, 
      Massachusetts General Hospital, Harvard Medical School, Boston, MA.
FAU - Montesi, Sydney B
AU  - Montesi SB
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, 
      Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
LA  - eng
GR  - K23 HL146942/HL/NHLBI NIH HHS/United States
GR  - K23 HL150331/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20211105
PL  - England
TA  - Rheumatol Adv Pract
JT  - Rheumatology advances in practice
JID - 101736676
PMC - PMC8570147
OTO - NOTNLM
OT  - interstitial lung disease
OT  - interstitial pneumonia with autoimmune features
OT  - lung fibrosis
EDAT- 2021/11/11 06:00
MHDA- 2021/11/11 06:01
PMCR- 2021/11/05
CRDT- 2021/11/10 06:47
PHST- 2021/02/08 00:00 [received]
PHST- 2021/03/16 00:00 [accepted]
PHST- 2021/11/10 06:47 [entrez]
PHST- 2021/11/11 06:00 [pubmed]
PHST- 2021/11/11 06:01 [medline]
PHST- 2021/11/05 00:00 [pmc-release]
AID - rkab051 [pii]
AID - 10.1093/rap/rkab051 [doi]
PST - epublish
SO  - Rheumatol Adv Pract. 2021 Nov 5;5(Suppl 2):ii1-ii9. doi: 10.1093/rap/rkab051. 
      eCollection 2021 Nov.